Pfizer Inc. $PFE Shares Purchased by Westbourne Investments Inc.

Key Points

• Westbourne Investments increased its Pfizer stake by 53.7% in Q4, buying 44,324 shares to hold 126,799 shares valued at $3,157,000, which represents 1.5% of its portfolio and its 22nd-largest position.
• Pfizer beat Q4 estimates with $0.66 EPS (vs. $0.57) and $17.56B in revenue, but Wall Street sentiment is mixed — the consensus rating is Hold with an average target of $28.10 and recent downgrades from RBC and Bank of America.

Westbourne Investments Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 53.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,799 shares of the biopharmaceutical company's stock after acquiring an additional 44,324 shares during the period. Pfizer comprises 1.5% of Westbourne Investments Inc.'s investment portfolio, making the stock its 22nd biggest position. Westbourne Investments Inc.'s holdings in Pfizer were worth $3,157,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Mattern Wealth Management LLC lifted its stake in Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company's stock worth $228,000 after acquiring an additional 400 shares in the last quarter. Peak Asset Management LLC lifted its stake in Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company's stock worth $697,000 after acquiring an additional 402 shares in the last quarter. Quest Investment Management LLC lifted its stake in Pfizer by 1.3% during the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company's stock worth $809,000 after acquiring an additional 405 shares in the last quarter. Community Bank & Trust Waco Texas lifted its stake in Pfizer by 0.6% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company's stock worth $1,703,000 after acquiring an additional 412 shares in the last quarter. Finally, CVA Family Office LLC lifted its stake in Pfizer by 3.3% during the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company's stock worth $329,000 after acquiring an additional 413 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks highlights Pfizer’s deep and diversified oncology portfolio and pipeline, which could support longer-term revenue growth and investor sentiment ahead of quarterly results. How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
• Positive Sentiment: MarketWatch noted Pfizer stock rose Wednesday (while still underperforming the broader market), signaling intermittent buying interest that can counterbalance downside pressure from analyst moves. Pfizer Inc. stock rises Wednesday, still underperforms market
• Neutral Sentiment: Pfizer invited shareholders to a virtual Annual Meeting on April 23, 2026 — a standard corporate governance event that may include Q&A but is unlikely to move the stock materially by itself. Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
• Neutral Sentiment: ResearchAndMarkets published a biopharmaceutical CXO market report that cites major players including Pfizer; this industry-level report highlights outsourcing and supply-chain trends but has indirect impact on Pfizer’s near-term stock moves. $1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032
• Neutral Sentiment: Pfizer Limited announced a special window for dematerialisation of physical shares (local/regulatory matter) — relevant to regional investors but not material to NYSE-listed PFE’s valuation. Pfizer Limited Opens Special Window for Dematerialisation of Physical Shares
• Neutral Sentiment: Pfizer CEO Albert Bourla commented on U.S./European academic competitiveness vs. China — a strategic/PR item reflecting management views on R&D policy rather than an immediate stock catalyst. Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change
• Negative Sentiment: Bank of America cut its price target on PFE from $27 to $26 and set a Neutral rating — this reduces upside expectations and can apply downward pressure on the stock. Benzinga
• Negative Sentiment: RBC Capital reaffirmed a Sell rating on Pfizer, reinforcing bearish analyst sentiment and adding to near-term selling pressure from income-oriented or risk-averse investors. RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)
• Negative Sentiment: Yahoo Finance ran a piece explaining why Pfizer shares tumbled earlier in the week — investors should read it for details on the drivers of recent volatility (analyst moves, trading flows or company-specific news). Why Pfizer Stock Tumbled on Tuesday

Wall Street Analyst Weigh In

PFE has been the subject of several recent research reports. TD Cowen reiterated a "hold" rating on shares of Pfizer in a research note on Tuesday, December 30th. Argus raised Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Royal Bank Of Canada assumed coverage on Pfizer in a research report on Tuesday, February 24th. They set an "underperform" rating and a $25.00 price objective for the company. Morgan Stanley set a $27.00 price objective on Pfizer and gave the stock a "positive" rating in a research report on Tuesday, March 17th. Finally, UBS Group started coverage on Pfizer in a research report on Tuesday, January 6th. They set a "neutral" rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $28.10.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.23 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a fifty-two week low of $21.08 and a fifty-two week high of $28.75. The firm has a market capitalization of $154.84 billion, a PE ratio of 20.02 and a beta of 0.43. The stock's 50-day simple moving average is $27.19 and its 200-day simple moving average is $25.91.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the company earned $0.63 EPS. The business's quarterly revenue was down 1.2% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.